Trial Outcomes & Findings for Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain (NCT NCT03848143)

NCT ID: NCT03848143

Last Updated: 2026-07-30

Results Overview

Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

8 participants

Primary outcome timeframe

Baseline, 3 month follow up

Results posted on

2026-07-30

Participant Flow

Participant milestones

Participant milestones
Measure
BOTOX
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Round 1
STARTED
8
Round 1
COMPLETED
5
Round 1
NOT COMPLETED
3
Round 2
STARTED
5
Round 2
COMPLETED
3
Round 2
NOT COMPLETED
2

Reasons for withdrawal

Reasons for withdrawal
Measure
BOTOX
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Round 1
Lost to Follow-up
2
Round 1
Lack of Efficacy
1
Round 2
Lost to Follow-up
1
Round 2
Lack of Efficacy
1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
BOTOX
n=8 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Age, Continuous
55 years
STANDARD_DEVIATION 10.93 • n=8 Participants
Sex: Female, Male
Female
6 Participants
n=8 Participants
Sex: Female, Male
Male
2 Participants
n=8 Participants
Region of Enrollment
United States
8 participants
n=8 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month follow up

Population: The population analyzed were the participants that completed the first round.

Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)

Outcome measures

Outcome measures
Measure
BOTOX
n=5 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Change in Pain Intensity (Round 1)
3.91 units on a scale
Standard Deviation .86

PRIMARY outcome

Timeframe: Baseline, 6 month follow up

Population: Only 3 participants completed the 6 month follow up questionnaire and provided outcome data; therefore 3 participants were included in this analysis.

Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)

Outcome measures

Outcome measures
Measure
BOTOX
n=3 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Change in Pain Intensity (Round 2)
3.33 units on a scale
Standard Deviation 3.51

Adverse Events

BOTOX

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
BOTOX
n=8 participants at risk
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection. 1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C). Each patient will receive 50 U of onabotulinum toxin A. onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Nervous system disorders
Lip and Cheek Weakness
12.5%
1/8 • from enrollment until end of follow-up, up to 6 months
Nervous system disorders
Lip and Nose Numbness
12.5%
1/8 • from enrollment until end of follow-up, up to 6 months
Nervous system disorders
Facial Asymmetry
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months
Nervous system disorders
Speech Difficulty
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months
Nervous system disorders
Injection Site Pain
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months

Additional Information

Isabel Moreno Hay

University of Kentucky

Phone: 8593233440

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place